Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression

Journal of the European Academy of Dermatology and Venereology

Volumn 32, Issue 7, 2018, Pages 1138-1146

  Philipp Dormston, W G ^a   Muller K ^b   Novak, B ^c   Stromer K ^d   Termeer, C ^e   Hammann, U ^f   Glutsch, J W ^g   Krahn Senftleben G ^h   Lubbert H ^c   Koller, M ^b   Szeimies, R M ⁱ  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c Biofrontera Pharmaceuticals GmbH   (Germany)

^d Professional Association of German Dermatologists (BVDD)   (Germany)

^e Hautarztpraxis am Löwenmarkt   (Germany)

^f Hautarztpraxis Dr med Urte Hammann   (Germany)

^g Practice for Dermatology   (Germany)

^h Dermatology Practice   (Germany)

ⁱ Department of Dermatology and Allergology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE;

ACTINIC KERATOSIS; ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; BASAL CELL CARCINOMA; CANCER LOCALIZATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DESICCATION; DISEASE COURSE; DISEASE EXACERBATION; DOCUMENTATION; FEMALE; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON MELANOMA SKIN CANCER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; VISUAL ANALOG SCALE; CLINICAL TRIAL; MULTIPLE CANCER; PATHOLOGY; PATIENT-REPORTED OUTCOME; PROSPECTIVE STUDY; PSYCHOLOGY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PATIENT REPORTED OUTCOME MEASURES; PROSPECTIVE STUDIES; QUALITY OF LIFE; SKIN NEOPLASMS; SURVEYS AND QUESTIONNAIRES;

EID: 85040618622     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14703     Document Type: Article

References (54)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069–1080.
2. Eisemann N, Waldmann A, Geller AC et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 2014; 134: 43–50.
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Prävention von Hautkrebs: Kurzversion 1.1 [AWMF-Registernummer: 032/0520L] 2014. Available at: http://www.awmf.org/uploads/tx_szleitlinien/032-052OLk_Pravention_von_Hautkrebs_2014-04.pdf [last accessed 20 July 2017].
4. Ackerman AB. Solar keratosis is squamous cell carcinoma. Arch Dermatol 2003; 139: 1216–1217.
5. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol 2007; 157(Suppl 2): 18–20.
6. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523–2530.
7. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23–24.
8. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502–518.
9. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4–7.
10. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455–464.
11. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154–1159.
12. Lewis KG, Weinstock MA. Nonmelanoma skin cancer mortality (1988–2000): the Rhode Island follow-back study. Arch Dermatol 2004; 140: 837–842.
13. Gaulin C, Sebaratnam DF, Fernandez-Penas P. Quality of life in non-melanoma skin cancer. Australas J Dermatol 2015; 56: 70–76.
14. Werner RN, Stockfleth E, Connolly SM et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version. J Eur Acad Dermatol Venereol 2015; 29: 2069–2079.
15. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis 2012; 89: 241–250.
16. Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. Qual Life Res 1996; 5: 191–194.
17. Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004; 30: 525–529.
18. Steinbauer J, Koller M, Kohl E, Karrer S, Landthaler M, Szeimies RM. Quality of life in health care of non-melanoma skin cancer – results of a pilot study. J Dtsch Dermatol Ges 2011; 9: 129–135.
19. Chen T, Bertenthal D, Sahay A, Sen S, Chren MM. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol 2007; 143: 1386–1392.
20. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2007; 127: 1351–1357.
21. Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117: 399–405.
22. Esmann S, Vinding GR, Christensen KB, Jemec GB. Assessing the influence of actinic keratosis on patients’ quality of life: the AKQoL questionnaire. Br J Dermatol 2013; 168: 277–283.
23. Esmann S. Patients’ perspectives on actinic keratosis. Curr Probl Dermatol 2015; 46: 8–13.
24. Miller IM, Vinding G, Zarchi K, Esmann S, Murrell DF, Jemec GB. Differences in disease-specific quality of life in patients with actinic keratosis in Australia and Denmark. Acta Dermatovenerol Croat 2016; 24: 25–28.
25. Longo Imedio I, Serra-Guillen C. Adaptation and validation of the Spanish version of the Actinic Keratosis Quality of Life questionnaire. Actas Dermosifiliogr 2016; 107: 474–481.
26. Gibbons E, Casanas I, Comabella C, Fitzpatrick R. A structured review of patient-reported outcome measures for patients with skin cancer, 2013. Br J Dermatol 2013; 168: 1176–1186.
27. Black N. Patient-reported outcome measures in skin cancer. Br J Dermatol 2013; 168: 1151.
28. Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727–1736.
29. Tolley K, Kemmett D, Thybo S, Nasr R, Smethurst H. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective. Eur J Health Econ 2016; 17: 287–304.
30. EuroQol. EQ-5D 2017. Available at: https://euroqol.org/ [last accessed 20 July 2017].
31. Versteegh M, Vermeulen K, Evers S, de Wit GA, Prenger R, Stolk E. Dutch tariff for the five-level version of EQ-5D. Value Health 2016; 19: 343–352.
32. vanReenen M, Janssen B. EQ-5D-5L User Guide: EuroQol Research Foundation; 2015. https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf. [last accessed 20 July 2017].
33. Sakthong P, Charoenvisuthiwongs R, Shabunthom R. A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes. Health Qual Life Outcomes 2008; 6: 71.
34. Development OfEC-oa. Classifying educational programmes: manual for ISCED-97 implementation in OECD countries 1999. Available at: http://www.oecd.org/education/skills-beyond-school/1962350.pdf. [last accessed 20 July 2017]
35. McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. Health Qual Life Outcomes 2016; 14: 133.
36. Akritas MG, Arnold SF, Brunner E. Nonparametric hypotheses and rank statistics for unbalanced factorial designs. J Am Stat Assoc 1997; 92: 258–265.
37. Waalboer-Spuij R, Nijsten TE. A review on quality of life in keratinocyte carcinoma patients. G Ital Dermatol Venereol 2013; 148: 249–254.
38. Rudolph C, Schnoor M, Eisemann N, Katalinic A. Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010. J Dtsch Dermatol Ges 2015; 13: 788–797.
39. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013; 149: 541–547.
40. Fernandez-Figueras MT, Carrato C, Saenz X et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015; 29: 991–997.
41. Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol 2017; 31(Suppl 2): 5–7.
42. Lear W, Akeroyd JE, Mittmann N, Murray C. Measurement of utility in nonmelanoma skin cancer. J Cutan Med Surg 2008; 12: 102–106.
43. Seidler AM, Bramlette TB, Washington CV, Szeto H, Chen SC. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol Surg 2009; 35: 1776–1787.
44. Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 2010; 28: 1055–1064.
45. Soini EJ, Hallinen T, Sokka AL, Saarinen K. Cost-utility of first-line actinic keratosis treatments in Finland. Adv Ther 2015; 32: 455–476.
46. Littenberg B, Partilo S, Licata A, Kattan MW. Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med Decis Making 2003; 23: 480–488.
47. Chen SC, Bayoumi AM, Soon SL et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 2004; 9: 160–168.
48. Tennvall GR, Norlin JM, Malmberg I, Erlendsson AM, Haedersdal M. Health related quality of life in patients with actinic keratosis–an observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes 2015; 13: 111.
49. Greiner W, Weijnen T, Nieuwenhuizen M et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003; 4: 222–231.
50. Hinz A, Kohlmann T, Stobel-Richter Y, Zenger M, Brahler E. The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. Qual Life Res 2014; 23: 443–447.
51. Szende A, Janssen B. Cross-Country Analysis of EQ-5D Data. In Szende A, Janssen B, Cabases J, eds. Self-Reported Population Health: An International Perspective based on EQ-5D. Springer Netherlands, Dordrecht, 2014: 31–36.
52. Huber MB, Reitmeir P, Vogelmann M, Leidl R. EQ-5D-5L in the general German population: comparison and evaluation of three yearly cross-section surveys. Int J Environ Res Public Health 2016; 13: 343.
53. Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res 2007; 16: 571–575.
54. Wallwiener M, Simoes E, Sokolov AN, Brucker SY, Fasching PA, Graf J. Health-related quality of life in metastatic and adjuvant breast cancer patients. Geburtshilfe Frauenheilkd 2016; 76: 1065–1073.